Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Hypertension

Drug Information

Target Indication

Hypertension

Clinical Trial

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Non-alcoholic Fatty Liver Disease (NAFLD)

Heart Transplantation

Influenza

Meningococcal Meningitis

Axial Spondyloarthritis